KYORIN Pharmaceutical (4569) · InitiativeDropped
Development of a Drug Candidate Using Spirulina Genetic Modification Technology
First written in FY2023. 1 of 2 entries say "Dropped", first in FY2024-Q2. Latest entry: FY2024-Q2.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Joint development of genetic engineering technology for spirulina with ルーメンA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024-Q2DroppedAnnual report
「The following material contracts were terminated during the second quarter of the current consolidated fiscal year. ② Joint research and development Contract company: Kyorin Pharmaceutical Co., Ltd. (the Company) Description: Development of development candidates using spirulina genetic modification technology Counterparty: Lumen Country: United States Contract year: 2022」
The joint research and development agreement with Lumen for development candidates using spirulina genetic modification technology was terminated. - FY2023First statedAnnual report
「Development of a drug candidate using spirulina genetic modification technology; Lumen; United States; 2022.」
The Group disclosed a joint research and development agreement with Lumen for a drug candidate using spirulina genetic modification technology.